Core Viewpoint - AAR CORP. has initiated an underwritten public offering of 3,000,000 shares of its common stock, with an option for underwriters to purchase an additional 450,000 shares [1][2]. Group 1: Offering Details - The net proceeds from the offering will be used to repay outstanding borrowings under its unsecured revolving credit facility and for general corporate purposes, potentially including funding future acquisitions [2]. - Goldman Sachs & Co. LLC, Jefferies, and RBC Capital Markets, LLC are serving as joint book-running managers for the offering [2]. - The offering is made under a shelf registration statement on Form S-3, which was filed with the SEC and became effective on July 19, 2023 [2]. Group 2: Company Overview - AAR is a global aerospace and defense aftermarket solutions company, operating in over 20 countries and supporting commercial and government customers through four segments: Parts Supply, Repair & Engineering, Integrated Solutions, and Expeditionary Services [4].

Core Points - Artelo Biosciences, Inc. has announced the pricing of its public offering of 441,210 shares of common stock at $4.40 per share and pre-funded warrants at $4.399 per warrant, aiming for gross proceeds of approximately $2.0 million [1] - The offering is managed by R.F. Lafferty & Co., Inc. and is conducted under a "shelf" registration statement filed with the SEC [2] - The offering is expected to close on October 1, 2025, pending customary closing conditions [1] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6] - The company has a diversified pipeline addressing significant unmet medical needs, including anorexia, anxiety, and inflammation [6] - Artelo is led by an experienced executive team and collaborates with world-class researchers and digital-asset technology partners to maximize stakeholder value [6]

Core Viewpoint - Wellgistics Health, Inc. has announced a public offering of shares and associated warrants, indicating a strategic move to raise capital for its operations in pharmaceutical distribution and digital services [1] Company Summary - Wellgistics Health, Inc. is a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment [1] - The company is offering 7,142,862 shares of common stock at a public offering price of $0.70 per share [1] - Along with the shares, the company is also offering warrants to purchase an equal number of shares at the same price of $0.70 per share [1] - The warrants will be exercisable upon issuance and will expire five years thereafter [1] Industry Summary - The announcement reflects ongoing trends in the pharmaceutical distribution industry, particularly the integration of digital solutions and AI technologies [1] - The capital raised through this offering may be utilized to enhance the company's technological capabilities and expand its market presence [1]

Core Viewpoint - Outcrop Silver & Gold Corporation has announced a public offering of units to raise up to $20 million, aimed at funding exploration and drilling at its Santa Ana project in Colombia [1][4]. Offering Details - The offering consists of units priced at $0.35 each, with each unit comprising one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to purchase one common share at an exercise price of $0.55 for 24 months, with provisions for early expiry if the share price exceeds $0.75 for 20 consecutive trading days [2]. Agents and Fees - BMO Capital Markets is the sole bookrunner, with Research Capital Corporation as co-lead agent, and they will receive a fee of 6.0% of the gross proceeds from the offering [3][4]. Use of Proceeds - The net proceeds from the offering will be allocated for exploration and drilling at the Santa Ana project, as well as for general working capital [4]. Regulatory Approvals - The closing of the offering is anticipated around October 3, 2025, pending necessary regulatory approvals, including from the TSX Venture Exchange [5]. Company Overview - Outcrop Silver is focused on advancing its Santa Ana high-grade silver project in Colombia, emphasizing responsible mining practices and community engagement [7][8]. - The company aims to expand its mineral resources through strategic exploration initiatives, leveraging its experienced team [8].

Core Viewpoint - Jasper Therapeutics, Inc. has announced a public offering of common stock and warrants to raise approximately $30 million to support the development of briquilimab, a novel antibody therapy targeting mast cell driven diseases [1][3]. Group 1: Offering Details - The offering includes 11,670,707 shares of common stock priced at $2.43 per share, along with common warrants to purchase the same number of shares [1]. - Additionally, the offering includes pre-funded warrants for 675,000 shares, priced at $2.43 minus a nominal exercise price of $0.0001 per share [1][2]. - The gross proceeds from the offering are expected to be around $30 million, before deducting underwriting discounts and commissions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the advancement of briquilimab's preclinical and clinical development programs, as well as for general corporate purposes, including capital expenditures and working capital [3]. Group 3: Company Overview - Jasper Therapeutics is focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [7]. - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits signaling through the KIT receptor, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [7]. - The company is currently conducting clinical studies demonstrating the efficacy and safety of briquilimab in patients with CSU and CIndU [7].

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 27 million shares of common stock and associated warrants, aiming to raise approximately $9 million to fund research and development and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 27,000,000 shares of common stock and Series E and Series F warrants, priced at $0.335 per share, with total gross proceeds expected to be around $9 million before expenses [1][3]. - The Series E Warrants and Series F Warrants will have an exercise price of $0.335 per share, with Series E Warrants expiring in five years and Series F Warrants expiring in 12 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes two drug candidates, brilaroxazine (RP5063) and RP1208 [6].

Core Viewpoint - Rithm Capital Corp. has initiated an opportunistic underwritten public offering of Series E Fixed-Rate Cumulative Redeemable Preferred Stock, contingent on market conditions [1] Group 1: Offering Details - The terms of the Preferred Stock will be determined through negotiations between the Company and the underwriters [1] - The Company plans to apply for listing the Preferred Stock on the New York Stock Exchange under the symbol "RI" [1]

Core Viewpoint - Red Cat Holdings, Inc. has announced a public offering of 15,625,000 shares at a price of $9.60 per share, aiming to raise approximately $150 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about September 19, 2025, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,343,750 additional shares at the public offering price [1]. - Northland Capital Markets is the sole bookrunner, with Ladenburg Thalmann & Co. Inc. acting as co-manager for the transaction [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate and working capital purposes, including operating expenditures related to the new unmanned surface vessel division [2]. Group 3: Company Overview - Red Cat Holdings, Inc. is a U.S.-based provider of advanced drone and robotic solutions for defense and national security [5]. - The company develops American-made hardware and software through its subsidiaries, Teal Drones and FlightWave Aerospace, supporting military, government, and public safety operations [5]. - Red Cat is expanding into the maritime domain with its Blue Ops, Inc., focusing on uncrewed surface vessels (USVs) to enhance safety and mission effectiveness [5].

Core Viewpoint - AIRO Group Holdings, Inc. has successfully closed an upsized underwritten public offering of 4,830,000 shares of its common stock, indicating strong investor interest and confidence in the company's aerospace and defense technologies [1] Summary by Relevant Sections - **Offering Details** - The offering included the full exercise of the underwriters' option to purchase an additional 630,000 shares, demonstrating robust demand [1] - The gross proceeds from the offering, before deducting underwriting discounts and other expenses, highlight the financial strength of the company [1] - **Company Profile** - AIRO Group Holdings, Inc. specializes in advanced aerospace and defense technologies, positioning itself in a critical and growing industry [1]

Group 1 - Nebius Group N.V. announced the pricing of its underwritten public offering of $1 billion of Class A ordinary shares at a price of $92.50 per share [1] - The company has granted underwriters a 30-day option to purchase an additional $150 million of Class A ordinary shares [1]